Diabetes remission after bariatric surgery: Is it just the incretins?

International Journal of Obesity

Volumn 35, Issue , 2011, Pages S22-S25

  Laferrere B ^a  

^a St Luke's Roosevelt Hospital Center Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Diabetes; Gastric bypass; Gip; Glp 1; Incretin effect

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; OXYNTOMODULIN; PEPTIDE YY [3-36];

BARIATRIC SURGERY; BODY MASS; CONFERENCE PAPER; DIET THERAPY; ENERGY BALANCE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; JEJUNOILEAL BYPASS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RECURRENT DISEASE; STOMACH BYPASS; STOMACH EMPTYING; WEIGHT REDUCTION;

BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INCRETINS; INTESTINE, SMALL; OBESITY, MORBID; REMISSION INDUCTION; WEIGHT LOSS;

EID: 80052719514     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2011.143     Document Type: Article

References (45)

1. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Bariatric surgery: A systematic review and meta-analysis. JAMA 2004; 292: 1724–1737.
2. Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Adjustable gastric banding and conventional therapy for type 2 diabetes: A randomized controlled trial. JAMA 2008; 299: 316–323.
3. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610–630.
4. Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992; 15: 442–455.
5. Laferrère B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007; 30: 1709–1716.
6. Laferrère B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 2479–2485.
7. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987; 2: 1300–1304.
8. Holst JJ, Orskov C. Incretin hormonesFan update. Scand J Clin Lab Invest Suppl 2001; 234: 75–85.
9. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Human duodenal enteroendocrine cells: Sourceof both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006; 290: E550–E559.
10. Ebert R, Creutzfeldt W. Gastrointestinal peptides and insulin secretion. Diabetes Metab Rev 1987; 3: 1–26.
11. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492–498.
12. Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, Gjinovci A, Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 2004; 113: 635–645.
13. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001; 25: 781–792.
14. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541–R1544.
15. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999; 277: R910–R916.
16. D’Alessio DA, Prigeon RL, Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulinindependent processes. A physiological role of glucagon-like peptide I. Diabetes 1995; 44: 1433–1437.
17. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46–52.
18. Holst JJ. Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006; 49: 253–260.
19. Sarson DL, Scopinaro N, Bloom SR. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 1981; 5: 471–480.
20. Naslund E, Gryback P, Hellstrom PM, Jacobsson H, Holst JJ, Theodorsson E, Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997; 21: 387–392.
21. Naslund E, Backman L, Holst JJ, Theodorsson E, Hellstrom PM. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 1998; 8: 253–260.
22. Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL, Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006; 91: 1735–1740.
23. Sarson DL, Besterman HS, Bloom SR. Radioimmunoassay of gastric inhibitory polypeptide and its release in morbid obesity and after jejuno-ileal bypass [proceedings]. J Endocrinol 1979; 81: 155P–156P.
24. Lauritsen KB, Christensen KC, Stokholm KH. Gastric inhibitory polypeptide (GIP) release and incretin effect after oral glucose in obesity and after jejunoileal bypass. Scand J Gastroenterol 1980; 15: 489–495.
25. Halverson JD, Kramer J, Cave A, Permutt A, Santiago J. Altered glucose tolerance, insulin response, and insulin sensitivity after massive weight reduction subsequent to gastric bypass. Surgery 1982; 92: 235–240.
26. Kindel TL, Yoder SM, Seeley RJ, D’Alessio DA, Tso P. Duodenal-Jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. J Gastrointest Surg 2009; 13: 1762–1772.
27. Verdich C, Toubro S, Buemann B, Lysgard MJ, Juul HJ, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satietyFeffect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001; 25: 1206–1214.
28. Cohen RV, Schiavon CA, Pinheiro JS, Correa JL, Rubino F. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: A report of 2 cases. Surg Obes Relat Dis 2007; 3: 195–197.
29. Naslund E, Backman L, Holst JJ, Theodorsson E, Hellstrom PM. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 1998; 8: 253–260.
30. Bose M, Teixeira J, Scherer PE, Pi-Sunyer FX, Bawa B, Laferrère B. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes 2010; 2: 47–55.
31. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353: 249–254.
32. Kellogg TA, Bantle JP, Leslie DB, Redmond JB, Slusarek B, Swan T, Postgastric bypass hyperinsulinemic hypoglycemia syndrome: Characterization and response to a modified diet. Surg Obes Relat Dis 2008; 4: 492–499.
33. Farilla L, Bulotta A, Hirshberg B, Li CS, Khoury N, Noushmehr H, Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149–5158.
34. Cornu M, Yang JY, Jaccard E, Poussin C, Widmann C, Thorens B. Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop. Diabetes 2009; 58: 1816–1825.
35. McLaughlin T, Peck M, Holst J, Deacon C. Reversible hyperinsulinemic hypoglycemia after gastric bypass: A consequence of altered nutrient delivery. J Clin Endocrinol Metab 2010; 95: 1851–1855.
36. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: A new perspective for an old disease. Ann Surg 2004; 239: 1–11.
37. Pacheco D, de Luis DA, Romero A, Gonzalez SM, Conde R, Izaola O, The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg 2007; 194: 221–224.
38. Patriti A, Facchiano E, Annetti C, Aisa MC, Galli F, Fanelli C, Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg 2005; 15: 1258–1264.
39. Strader AD, Vahl TP, Jandacek RJ, Woods SC, D’Alessio DA, Seeley RJ. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 2005; 288: E447–E453.
40. Horowitz M, Collins PJ, Harding PE, Shearman DJ. Gastric emptying after gastric bypass. Int J Obes 1986; 10: 117–121.
41. Gill RS, Birch DW, Shi X, Sharma AM, Karmali S. Sleeve gastrectomy and type 2 diabetes mellitus: A systematic review. Surg Obes Relat Dis 2010; 6: 707–713.
42. Olivan B, Teixeira J, Bose M, Bawa B, Chang T, Summe H, Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. Ann Surg 2009; 249: 948–953.
43. Laferrère B, Swerdlow N, Bawa B, Arias S, Bose M, Olivan B, Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 4072–4076.
44. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623–1630.
45. Bose M, Machineni S, Olivan B, Teixeira J, McGinty JJ, Bawa B, Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring) 2010; 18: 1085–1091.